The Royal Institution Christmas Lecture
“The Truth about AI” December 2023 Manus Neurodynamica’s CEO, Dr Rutger Zietsma was a guest on the Royal Institution’s 2023 Christmas Lectures – “The Truth about AI”, which were hosted by Mike Wooldridge, Professor of AI at Oxford University and Director for AI at The Alan Turing Institute in … Read more
Industry Forum participation at the Future of Parkinson’s Disease Conference
Manus Neurodynamica’s CEO, Dr Rutger Zietsma presented to the Parkinson’s community at the Future of Parkinson’s Disease conference that was held November 30 – December 3, in Austin, Texas, US. The joint annual conference is hosted by the Parkinson’s Foundation and the Parkinson Study Group. During the Industry Iorum on the 1st of … Read more
Prix Galien USA 2023 Nomination for Manus Neurodynamica Ltd in startup category
We were honoured to attend the Prix Galien USA 2023 awards ceremony on the 26th of October 2023 in New York. The Prix Galien Awards commemorate unique medical and pharmaceutical products that impact patient care through innovation. Manus Neurodynamica was one of the nominees in the start-up category. We … Read more
Appointments of VP of Sales, CTO, CFO and Chairman strengthens the Manus team, broadening the skillsets and expertise of the Group
Edinburgh, UK – 1st of June 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces it has expanded its Senior Management team with the appointments of VP of Sales, Roberto Marcucci, Chief Technology Officer, Dr David Bramwell, Chief Financial Officer, Phil Pattison … Read more
Manus secures £2.6m to support the commercialisation of NeuroMotor PenTM
Edinburgh, UK – 25 May 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has closed a £2.6m funding round to support the commercialisation of its innovative NeuroMotor PenTM – a medical device to aid diagnosis and monitoring of neuromotor … Read more
Agreement signed with Medispa to integrate NeuroMotor PenTM into Prevention Suite
Prevention Suite platform used by more than 10,000 pharmacies in Italy, Spain and Portugal. Partnership to be showcased at the annual Cosmofarma Exhibition in Bologna, Italy this weekend Edinburgh, UK – 5 May 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces … Read more
Agreement with Johnson & Johnson to use Neuromotor PenTM to detect neuromotor ad-verse effects following CAR T-cell therapy
Manus named awardee in ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire Challenge Edinburgh, UK – 24 April 2023: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been named an awardee in the ‘Improving Detection of Neurotoxicity in Immunotherapies’ QuickFire … Read more
Manus joins ABHI US Accelerator 2022 cohort
12-month programme allows Manus to utilise ABHI’s expertise and connections within the US to strengthen strategy and de-risk market entry Edinburgh, UK – 22 February 2022: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announced that it has joined the Association of British … Read more
Appointment of Non-Executive Director and additional key hires
Appointment of Dr Guy Wood-Gush to the Board of Directors, and hires of Senior Data Scientist and Technical Operations and Project Manager Edinburgh, UK – 21 December 2021: Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces the appointment of Dr Guy Wood-Gush … Read more
FDA grants Breakthrough Device Designation for the Manus NeuroMotor Pen™
Designation provides priority regulatory review of the Manus NeuroMotor Pen™ designed to aid the diagnoses of Parkinson’s Disease Manus Neurodynamica Limited (“Manus”), which develops and markets products and technologies for neuromotor assessment, announces that it has been granted Breakthrough Designation by the U.S. Food and Drug Administration (“FDA”) for … Read more